AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at William Blair cut their FY2025 earnings per share (EPS) estimates for AbbVie in a research note issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the company will post earnings per share of $11.86 for the year, down from their prior forecast of $12.27. William Blair has a "Outperform" rating on the stock. The consensus estimate for AbbVie's current full-year earnings is $11.17 per share.
ABBV has been the subject of several other reports. Barclays lifted their target price on AbbVie from $185.00 to $195.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 27th. BMO Capital Markets lifted their price objective on AbbVie from $187.00 to $195.00 and gave the company an "outperform" rating in a report on Monday, February 5th. Raymond James lifted their price objective on AbbVie from $181.00 to $189.00 and gave the company an "outperform" rating in a report on Monday, February 5th. Truist Financial lifted their price objective on AbbVie from $180.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, February 6th. Finally, Guggenheim lifted their price objective on AbbVie from $188.00 to $190.00 and gave the company a "buy" rating in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and a consensus price target of $177.43.
View Our Latest Analysis on ABBV
AbbVie Trading Up 0.2 %
Shares of NYSE:ABBV traded up $0.41 on Thursday, hitting $164.66. 4,479,202 shares of the company's stock were exchanged, compared to its average volume of 5,637,517. AbbVie has a 12 month low of $130.96 and a 12 month high of $182.89. The stock has a market capitalization of $291.56 billion, a price-to-earnings ratio of 60.89, a price-to-earnings-growth ratio of 2.09 and a beta of 0.58. The business's 50 day simple moving average is $175.79 and its two-hundred day simple moving average is $159.94. The company has a debt-to-equity ratio of 5.02, a current ratio of 0.87 and a quick ratio of 0.76.
AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, February 2nd. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.76 by $0.03. AbbVie had a return on equity of 162.28% and a net margin of 8.95%. The business had revenue of $14.30 billion during the quarter, compared to the consensus estimate of $14.02 billion. During the same period last year, the company earned $3.60 earnings per share. The business's revenue for the quarter was down 5.4% compared to the same quarter last year.
AbbVie Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be paid a dividend of $1.55 per share. The ex-dividend date is Friday, April 12th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.77%. AbbVie's payout ratio is 227.11%.
Insider Transactions at AbbVie
In other news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the business's stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $173.71, for a total transaction of $9,184,047.70. Following the sale, the executive vice president now owns 243,944 shares in the company, valued at $42,375,512.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Richard A. Gonzalez sold 138,616 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $177.27, for a total value of $24,572,458.32. Following the sale, the chief executive officer now owns 519,099 shares in the company, valued at $92,020,679.73. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Azita Saleki-Gerhardt sold 52,870 shares of the company's stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the sale, the executive vice president now owns 243,944 shares in the company, valued at approximately $42,375,512.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 383,324 shares of company stock worth $67,780,003. Insiders own 0.25% of the company's stock.
Institutional Investors Weigh In On AbbVie
A number of large investors have recently bought and sold shares of the company. Lokken Investment Group LLC boosted its position in AbbVie by 3.6% in the fourth quarter. Lokken Investment Group LLC now owns 1,666 shares of the company's stock valued at $258,000 after buying an additional 58 shares during the last quarter. Aspen Wealth Strategies LLC lifted its holdings in AbbVie by 0.5% in the fourth quarter. Aspen Wealth Strategies LLC now owns 11,463 shares of the company's stock valued at $1,776,000 after acquiring an additional 61 shares during the period. Marks Group Wealth Management Inc lifted its holdings in AbbVie by 2.9% in the fourth quarter. Marks Group Wealth Management Inc now owns 2,254 shares of the company's stock valued at $349,000 after acquiring an additional 63 shares during the period. Avion Wealth lifted its holdings in AbbVie by 11.9% in the fourth quarter. Avion Wealth now owns 612 shares of the company's stock valued at $95,000 after acquiring an additional 65 shares during the period. Finally, White Pine Capital LLC lifted its holdings in AbbVie by 1.2% in the fourth quarter. White Pine Capital LLC now owns 5,498 shares of the company's stock valued at $852,000 after acquiring an additional 65 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.
About AbbVie
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
